ENXTPA:BOI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More Details


Snowflake Analysis

Flawless balance sheet, good value and pays a dividend.


Similar Companies

Share Price & News

How has Boiron's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BOI is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BOI's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-1.9%

BOI

-0.5%

FR Pharmaceuticals

1.1%

FR Market


1 Year Return

13.3%

BOI

-0.3%

FR Pharmaceuticals

-2.6%

FR Market

Return vs Industry: BOI exceeded the French Pharmaceuticals industry which returned -1.8% over the past year.

Return vs Market: BOI exceeded the French Market which returned -3% over the past year.


Shareholder returns

BOIIndustryMarket
7 Day-1.9%-0.5%1.1%
30 Day0.6%4.9%15.2%
90 Day11.7%0.3%11.6%
1 Year16.9%13.3%3.1%-0.3%-0.6%-2.6%
3 Year-44.0%-48.9%22.2%9.0%16.8%7.1%
5 Year-44.7%-51.5%29.7%7.7%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is Boiron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Boiron undervalued compared to its fair value and its price relative to the market?

16.96x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BOI (€38.8) is trading above our estimate of fair value (€29.14)

Significantly Below Fair Value: BOI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BOI is good value based on its PE Ratio (17x) compared to the XE Pharmaceuticals industry average (23.1x).

PE vs Market: BOI is good value based on its PE Ratio (17x) compared to the French market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: BOI is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: BOI is good value based on its PB Ratio (1.4x) compared to the FR Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Boiron forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

31.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOI's forecast earnings growth (31.7% per year) is above the savings rate (0.6%).

Earnings vs Market: BOI's earnings (31.7% per year) are forecast to grow faster than the French market (25.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BOI's revenue is expected to decline over the next 3 years (-1.9% per year).

High Growth Revenue: BOI's revenue is forecast to decline over the next 3 years (-1.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOI's Return on Equity is forecast to be low in 3 years time (8.4%).


Next Steps

Past Performance

How has Boiron performed over the past 5 years?

-15.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BOI has a large one-off loss of €35.7M impacting its June 30 2020 financial results.

Growing Profit Margin: BOI's current net profit margins (7.2%) are higher than last year (6.1%).


Past Earnings Growth Analysis

Earnings Trend: BOI's earnings have declined by 15.5% per year over the past 5 years.

Accelerating Growth: BOI's earnings growth over the past year (12.8%) exceeds its 5-year average (-15.5% per year).

Earnings vs Industry: BOI earnings growth over the past year (12.8%) underperformed the Pharmaceuticals industry 13.2%.


Return on Equity

High ROE: BOI's Return on Equity (8.3%) is considered low.


Next Steps

Financial Health

How is Boiron's financial position?


Financial Position Analysis

Short Term Liabilities: BOI's short term assets (€415.2M) exceed its short term liabilities (€183.2M).

Long Term Liabilities: BOI's short term assets (€415.2M) exceed its long term liabilities (€92.5M).


Debt to Equity History and Analysis

Debt Level: BOI's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: BOI's debt to equity ratio has reduced from 2.4% to 1% over the past 5 years.

Debt Coverage: BOI's debt is well covered by operating cash flow (1750.1%).

Interest Coverage: BOI earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Boiron current dividend yield, its reliability and sustainability?

2.71%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BOI's dividend (2.71%) is higher than the bottom 25% of dividend payers in the French market (1.41%).

High Dividend: BOI's dividend (2.71%) is low compared to the top 25% of dividend payers in the French market (4.66%).


Stability and Growth of Payments

Stable Dividend: BOI's dividend payments have been volatile in the past 10 years.

Growing Dividend: BOI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (45.9%), BOI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BOI's dividends in 3 years are forecast to be well covered by earnings (42.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Valérie Lorentz-Poinsot (51 yo)

1.83yrs

Tenure

€841,100

Compensation

Ms. Valerie Lorentz-Poinsot serves as General Manager and Director of Development of Boiron SA and served as its Deputy General Manager since July 01, 2011. Ms. Lorentz-Poinsot has been an Executive Direct...


CEO Compensation Analysis

Compensation vs Market: Valérie's total compensation ($USD1.00M) is above average for companies of similar size in the French market ($USD746.22K).

Compensation vs Earnings: Valérie's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Valérie Lorentz-Poinsot
GM & Executive Director1.83yrs€841.10k0.010%
€ 67.4k
Jean-Christophe Bayssat
Deputy GM4.83yrs€1.18mno data
Eric Lambert
Administrative & Financial Director0.83yrno datano data
David Soussan
Group Marketing Director0.83yrno datano data
Patrice Varraut
Sales Director0.83yrno datano data
Christine Place
Deputy General Managerno datano datano data
Fabrice Rey
Group Treasurer19yrsno datano data

1.3yrs

Average Tenure

Experienced Management: BOI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Valérie Lorentz-Poinsot
GM & Executive Director1.83yrs€841.10k0.010%
€ 67.4k
Michel Bouissou
Independent Director10.5yrs€45.63kno data
Bruno Grange
Director18.5yrs€16.22kno data
Thierry Boiron
Chairman of the Board of Directors9.33yrs€296.09k3.4%
€ 22.9m
Jean-Pierre Boyer
Director20.5yrs€31.77k0.020%
€ 134.8k
Michèle Boiron
Director24.17yrs€13.03k1.55%
€ 10.4m
Jacky Abécassis
Director33.5yrs€13.03kno data
Christine Boyer-Boiron
Director17.5yrs€13.03k1.13%
€ 7.6m
Stéphanie Chesnot
Director10.67yrs€31.77k0.030%
€ 202.2k
Virginie Heurtaut
Director7.5yrs€13.03k0.030%
€ 202.2k
Grégory Walter
Employee Shareholder Representative Director3.5yrs€57.98kno data
Christine Boutin
Employee Representative Director2.42yrs€92.44kno data

10.6yrs

Average Tenure

63yo

Average Age

Experienced Board: BOI's board of directors are seasoned and experienced ( 10.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Boiron SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Boiron SA
  • Ticker: BOI
  • Exchange: ENXTPA
  • Founded: 1932
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €674.075m
  • Shares outstanding: 17.51m
  • Website: https://www.boiron.com

Number of Employees


Location

  • Boiron SA
  • 2, avenue de l’Ouest Lyonnais
  • Messimy
  • Rhône-Alpes
  • 69510
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOIR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
BOIENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 1992
BONDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
0DTFLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
BOIPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 1992

Biography

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded home...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 18:51
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.